Synthetic biomarkers

01Overview and value chain

Markers: [EC: IVDR 2017/746 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union)]

Synthetic biomarkers are engineered, exogenous reporter molecules administered to a patient before a diagnostic sample is taken, designed to generate an amplified, easily measured signal that correlates with disease activity — unlike an endogenous biomarker, which the body must produce on its own at detectable levels. Glympse Bio’s activity-based nanosensors carry peptide substrates that disease-associated proteases cleave in vivo, releasing small reporter fragments that concentrate in urine for mass-spectrometry or paper-test readout, with the underlying protease-detection and fluorogenic-substrate chemistry documented in peer-reviewed publications and patent filings. Earli’s synthetic-biomarker platform uses engineered constructs (patented as “methods and compositions for synthetic biomarkers”) that, once localized to a tumor, produce a detectable signal amplifying an otherwise-undetectable early-stage cancer, with data presented at AACR and published in Nature Communications. Owlstone Medical’s EVOC (exogenous volatile organic compound) probes are administered and then metabolized differently by diseased versus healthy tissue, producing a distinct breath-VOC signature read by its Breath Biopsy platform; the company won a $49.1 million ARPA-H award to develop at-home breath-based cancer-detection tests. ZymoSense’s NanoAssay platform measures enzyme activity directly via an engineered nanosensor substrate, launched as a next-generation alternative to conventional enzyme-activity assays.

The key directions of synthetic biomarkers are:

1. Activity-based nanosensors (Activity-Based Nanosensors): protease-cleavable peptide-nanoparticle conjugates that release a urine- or blood-detectable reporter fragment in proportion to disease-associated protease activity — Glympse Bio.
2. Synthetic biomarker gene circuits (Synthetic Biomarker Gene Circuits): engineered constructs localized to diseased tissue that amplify an otherwise sub-detectable signal into a measurable readout — Earli.
3. Exogenous volatile-organic-compound probes (EVOC Probes): administered compounds metabolized differently by diseased tissue, producing a distinct breath-VOC signature — Owlstone Medical.
4. Engineered enzyme-activity sensors (Enzyme Activity Sensors): nanosensor substrates that directly report enzyme activity levels as a diagnostic readout — ZymoSense.

Sectoral value chain

[probe/reporter/circuit design] ──> [administration to patient] ──> [in-vivo signal generation]
                                                    │
                                       (sample collection: urine/breath/blood)
                                                    │
                                                    ▼
[regulatory approval & clinical adoption] <─── [detection & readout] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Activity-based sensing (Activity-Based Nanosensors): nanoparticle-conjugated peptide substrates cleaved by disease-associated proteases release a reporter that concentrates in an easily sampled biofluid, amplifying a signal the disease itself would not otherwise produce.
• Synthetic gene circuits (Synthetic Biomarker Gene Circuits): engineered genetic constructs that localize to and are activated by diseased tissue, producing a measurable output signal disproportionate to the underlying disease burden.
• Exogenous VOC metabolism (EVOC Probes): administered compounds are metabolized differently by diseased versus healthy tissue, and the resulting distinct volatile-organic-compound breath signature is captured non-invasively.

02US

The US hosts the deepest bench of synthetic-biomarker platform companies, spanning activity-based nanosensors, synthetic gene circuits and engineered enzyme-activity assays, largely still in clinical-stage development.

Glympse Bio, Earli, ZymoSense, FDA

• Glympse Bio: develops activity-based nanosensors whose protease-cleavable substrates release reporter fragments detectable in urine, with the underlying fluorogenic-substrate and protease-detection chemistry documented in peer-reviewed journals and multiple patent filings.
• Earli: holds a patent for “methods and compositions for synthetic biomarkers” and presented early-cancer-detection data at AACR annual meetings and in Nature Communications, engineering constructs that localize to tumor tissue and amplify an otherwise sub-detectable signal.
• ZymoSense: launched the NanoAssay platform, an engineered-nanosensor alternative to conventional enzyme-activity measurement, positioned as a next-generation enzyme assay tool.
• FDA framework: synthetic-biomarker probes intended for clinical diagnostic use require FDA review as combination products (probe plus detection assay), with most platforms in this category still in IND-stage clinical development rather than commercial FDA-approved diagnostics.

03CN

No dedicated Chinese synthetic-biomarker (engineered exogenous reporter) company cleared source confirmation as of 2026; China’s biomarker research activity in this period is concentrated on endogenous tumor-biomarker panels rather than administered synthetic probes.

endogenous-biomarker focus, NMPA, research gap

• Endogenous-biomarker emphasis: Chinese oncology-biomarker development and market activity tracked in 2026 industry reporting centers on conventional (endogenous) tumor-marker panels and multi-omic profiling rather than administered synthetic/exogenous reporter probes.
• Research and import pathway: to the extent synthetic-biomarker technologies reach Chinese clinical use, the pathway runs through NMPA review of imported diagnostic-agent/assay combinations rather than a domestic originator platform at this stage.
• NMPA framework: any synthetic-biomarker probe and its paired detection assay would register under NMPA as a combination diagnostic product, following the same review track as imported activity-based or breath-VOC diagnostics.

04EU

Europe’s synthetic-biomarker tier is anchored by Owlstone Medical, a UK breath-biomarker specialist with a material US operating presence.

Owlstone Medical, EVOC probes, EMA

• Owlstone Medical (Cambridge, UK): its EVOC (exogenous volatile organic compound) probes are metabolized differently by diseased versus healthy tissue, producing a distinct breath-VOC signature captured by its Breath Biopsy platform; the company won a $49.1 million ARPA-H award to develop at-home breath-based cancer-detection tests.
• EMA/IVDR framework: synthetic-biomarker diagnostic combinations (probe plus breath or biofluid assay) sold in the EU fall under EMA review for the administered probe and IVDR 2017/746 conformity assessment for the paired detection assay.

05Leading companies and research institutes

06Tech stack and innovations

The stack converts an engineered, exogenous molecule into a disease-activity signal amplified far beyond what an endogenous biomarker alone could produce, read out via mass spectrometry, breath analysis or an engineered sensor.

1. Protease-activatable nanosensors (Activity-Based Nanosensors):
   • Glympse Bio’s peptide-nanoparticle conjugates are cleaved by disease-associated proteases in vivo, releasing small reporter fragments that clear into urine at concentrations far exceeding what the endogenous disease process alone would generate.
2. Synthetic gene-circuit reporters (Synthetic Biomarker Gene Circuits):
   • Earli’s engineered constructs localize to tumor tissue and produce an amplified reporter output, aiming to catch cancers before they would be detectable via conventional imaging or endogenous-biomarker blood tests.
3. Exogenous VOC breath probes (EVOC Probes):
   • Owlstone Medical’s EVOC probes are metabolized differently by diseased tissue, and the Breath Biopsy platform captures the resulting distinct volatile-organic-compound signature non-invasively from a breath sample.
4. Engineered enzyme-activity sensors (Enzyme Activity Sensors):
   • ZymoSense’s NanoAssay substrate directly reports enzyme-activity levels, positioned as a faster, more scalable alternative to conventional enzyme-assay methods.

07Value chains and production pipelines

Industrial pipeline of a synthetic-biomarker diagnostic (FDA combination product / EMA + IVDR 2017/746)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Probe/reporter/circuit │ ───> │ 2. Administration to     │
│    design                  │      │    patient                 │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Sample collection      │ <─── │ 3. In-vivo signal         │
│                            │      │    generation               │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Detection & readout    │ ───> │ 6. Regulatory approval &  │
│                            │      │    clinical adoption        │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Probe, reporter or circuit design

The exogenous molecule or genetic construct is engineered to respond specifically to a disease-associated process — protease activity (Glympse Bio), tumor localization (Earli), differential tissue metabolism (Owlstone Medical) or direct enzyme activity (ZymoSense).

Stage 2: Administration to patient

The synthetic biomarker probe is delivered to the patient — by injection, inhalation or ingestion depending on the platform — ahead of the sample-collection window.

Stage 3: In-vivo signal generation

The disease-associated process acts on the probe (cleaving it, differentially metabolizing it, or triggering circuit expression), converting it into a detectable reporter signal amplified beyond what the endogenous disease process alone would produce.

Stage 4: Sample collection

A urine, breath or blood sample is collected after the probe has had sufficient time in vivo to generate its reporter signal.

Stage 5: Detection and readout

Mass spectrometry, a paper-based lateral-flow test, GC-MS breath analysis or an engineered sensor platform quantifies the reporter signal to produce a disease-activity readout.

Stage 6: Regulatory approval and clinical adoption

The probe and its paired detection assay undergo FDA combination-product review (US) or EMA plus IVDR conformity assessment (EU), with most platforms in this category still generating the clinical-validation data needed to reach that stage.